Drugs /

adenovirus expressing mutant hpv e6/e7

Back to Drugs List

Overview

NCI Definition [1]:
A cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of adenovirus expressing mutant HPV E6/E7, the adenovirus infects and expresses the E6 and E7 proteins. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.

Clinical Trials

View Clinical Trials for adenovirus expressing mutant hpv e6/e7

Adenovirus expressing mutant hpv e6/e7 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating adenovirus expressing mutant hpv e6/e7, 1 is phase 1 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for adenovirus expressing mutant hpv e6/e7 clinical trials.

Anal carcinoma, cervical carcinoma, and oropharyngeal carcinoma are the most common diseases being investigated in adenovirus expressing mutant hpv e6/e7 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Adenovirus Expressing Mutant Hpv E6/e7
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating adenovirus expressing mutant hpv e6/e7 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
adenovirus vaccine expressing mutant hpv e6 and e7, adenoviral-hpv e6e7 vaccine, adenoviral-expressing mutant hpv e6/e7, ad-e6e7, ad-e6/e7
NCIT ID [1]:
C157777

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.